Author: Ken Dropiewski

Biosense Webster Launches the OCTARAY™ Mapping Catheter with TRUEref™ Technology

The OCTARAY™ Mapping Catheter with TRUEref™ Technology provides physicians with the precise information needed for catheter ablation procedures that treat cardiac arrhythmias1,2† IRVINE, Calif., Sept. 6, 2022 /PRNewswire/ — Biosense Webster, Inc., part of Johnson & Johnson MedTech‡, today announced the release of the OCTARAY™ Mapping Catheter with TRUEref™ Technology powered by the […]

FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the US

SHENZHEN, China, Sept. 5, 2022 /PRNewswire/ — LifeTech Scientific Corporation (Stock Code: 1302.HK) is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance coverage in the United States, meaning that all patient enrollment of […]

Tenaya Therapeutics Announces FDA Clearance of Investigational New Drug Application and Initiation of Phase 1 Safety Study for TN-301, an HDAC6 Inhibitor for Heart Failure with Preserved Ejection Fraction

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced clearance of its Investigational New Drug (IND) application to begin clinical testing of […]

Internationally Renowned Clinician and Researcher Named Director of Interventional Cardiology at NYU Langone Health

NEW YORK, Sept. 1, 2022 /PRNewswire/ — Sunil V. Rao, MD, one of the world’s premier clinician-investigators in the field of interventional cardiology, has been named director of interventional cardiology at NYU Langone Health and the director of the cardiac catheterization laboratory at the Manhattan campus of NYU Langone. Dr. Rao, who will also […]

Healogics® is Raising Awareness of Peripheral Artery Disease and Healing Chronic Wounds During September

JACKSONVILLE, Fla., Sept. 2, 2022 /PRNewswire/ — The urgency of treating chronic wounds and foot ulcers cannot be ignored. In recognition of Peripheral Artery Disease (PAD) Awareness Month, Healogics® is empowering patients living with PAD, to seek timely wound care treatment critical for optimal healing and reducing the risk of amputations. Nearly 10 […]

Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CARLSBAD, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted an equity award on September 1, 2022 that was approved by the Compensation Committee of its Board […]

Viz.ai Receives FDA 510(k) Clearance for Automated RV/LV Analysis Algorithm

Part of the Viz PE Solution, new algorithm flags key patient risk indicator of pulmonary embolism severity SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an automated RV/LV ratio algorithm, a seamless […]

i-Cordis Receives SBIR Phase II Funding to Develop Treatment for Heart Failure with Preserved Ejection Fraction

BALTIMORE, Sept. 1, 2022 /PRNewswire/ — i-Cordis, LLC, an early-stage pharmaceutical company, has been awarded a Phase II Small Business Innovation Research (SBIR) grant for $1,548,708 from the National Heart, Lung, and Blood Institute (NHLBI) to further develop a potential immune-modulatory treatment for Heart Failure with preserved Ejection Fraction (HFpEF). HFpEF is one of […]

Venus Medtech announces 2022 interim results: quality and efficiency improvement, profitability focus, rapid progress in global presence

HANGZHOU, China, Sept. 1, 2022 /PRNewswire/ — On August 31, 2022, Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as “Venus Medtech”), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced its interim results for the six months ended June 30, 2022. Under repeated COVID-19 outbreaks, Venus Medtech intensified its […]